文献速递姑息放疗与转移瘤

PROGRAD:接受姑息放疗评估的住院患者预后观察性研究

PROGRAD - An observational study of the prognosis of inpatients evaluated for palliative radiotherapy.
PubMed 文献 · Radiother Oncol · 2018-04-03

这项前瞻性观察研究在巴西一家大型转诊癌症中心纳入333例申请姑息放疗的住院患者,应用中位生存期评估预后,全队列中位生存期为73天。Palliative Prognostic Index(PPI)和Number of Risk Factors(NRF)均可将患者分为预后显著不同的亚组,或有助于医疗系统制定优先级标准、促进公平。

要点

  • 申请姑息放疗的住院患者总体中位生存期仅73天,预后较差。
  • PPI≤2、2.5–4、>4组中位生存期分别为120、55、39天(p<.0001)。
  • NRF 0–1、2、3组中位生存期分别为129、73、40天(p<.0001)。

核心结论

  • 申请姑息放疗的住院患者总体生存较差,中位生存期为73天。
  • PPI和NRF可定义预后不同的亚组,或有助于医院和医疗系统标准化优先级标准并促进公平。

研究设计与样本

  • 应用Palliative Prognostic Index(PPI)和Survival Prediction Score using Number of Risk Factors(NRF)进行预后评估。
  • 主要终点为总生存期,次要终点为按PPI和NRF分层的生存期;ClinicalTrials.gov注册号NCT02312791。

主要发现

  • 全队列中位生存期为73天。
  • PPI≤2组中位生存期120天;PPI 2.5–4组55天(HR 1.84;95% CI 1.07–3.16);PPI>4组39天(HR 3.45;95% CI 2.07–5.74)(p<.0001)。
  • NRF 0–1组中位生存期129天;NRF 2组73天(HR 1.74;95% CI 0.89–3.38);NRF 3组40天(HR 2.95;95% CI 1.50–5.78)(p<.0001)。

关键数值与推荐

  • PPI分层:≤2、2.5–4、>4三组中位生存期分别为120、55、39天,组间比较p<.0001。
  • NRF分层:0–1、2、3三组中位生存期分别为129、73、40天,组间比较p<.0001。
  • PPI 2.5–4 vs ≤2的HR为1.84(95% CI 1.07–3.16);PPI>4 vs ≤2的HR为3.45(95% CI 2.07–5.74)。
  • NRF 2 vs 0–1的HR为1.74(95% CI 0.89–3.38);NRF 3 vs 0–1的HR为2.95(95% CI 1.50–5.78)。

临床怎么用

  • 对申请姑息放疗的住院患者,可用PPI和NRF进行预后分层,识别中位生存期较短(如PPI>4或NRF 3)的高危亚组。
  • 研究提示该分层或可帮助医院和医疗系统标准化姑息放疗优先级标准,促进资源分配的公平性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Low-and-middle-income countries have resource constraints and waiting lists for radiotherapy (RT). In this context, we sought to determine the survival of inpatients evaluated for palliative RT in a large referral cancer center in Brazil. MATERIAL AND METHODS: From November 2014 through December 2015, we enrolled 333 inpatients with palliative RT evaluation requests in this prospective observational study. We applied Palliative Prognostic Index (PPI) and Survival Prediction Score using Number of Risk Factors (NRF). Primary endpoint was overall survival. Secondary endpoints were survival by PPI and NRF. (ClinicalTrials.gov number, NCT02312791). RESULTS: Median survival (MS) for the entire cohort was 73 days. PPI ≤2 had MS of 120 days; PPI 2.5-4 had MS of 55 days (HR 1.84; 95% CI, 1.07-3.16); PPI >4 had MS of 39 days (HR 3.45; 95% CI, 2.07-5.74) (p < .0001). NRF 0-1 had MS of 129 days; NRF 2 had MS of 73 days (HR 1.74; 95% CI 0.89-3.38); NRF 3 had MS of 40 days (HR 2.95; 95% CI, 1.50-5.78) (p < .0001). CONCLUSION: Inpatients with palliative RT requests seem to have an overall poor survival. PPI and NRF can define subgroups with different prognosis. This could help hospitals and healthcare systems to standardize criteria for prioritization and contribute for fairness.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Chen ATC, Mauro GP, Gabrielli F, et al. PROGRAD - An observational study of the prognosis of inpatients evaluated for palliative radiotherapy. Radiother Oncol. 2018. PMID: 29625809. doi:10.1016/j.radonc.2018.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。